The terminology issue for myeloid-derived suppressor cells

Comment

Dmitry I Gabrilovich et al. Cancer Res. 2007.

. 2007 Jan 1;67(1):425; author reply 426.

doi: 10.1158/0008-5472.CAN-06-3037.

No abstract available

Comment in

Re: the terminology issue for myeloid-derived suppressor cells.
Krystal G, Sly L, Antignano F, Ho V, Ruschmann J, Hamilton M. Krystal G, et al. Cancer Res. 2007 Apr 15;67(8):3986. doi: 10.1158/0008-5472.CAN-07-0211. Cancer Res. 2007. PMID: 17440115 No abstract available.

CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells.
Yang R, Cai Z, Zhang Y, Yutzy WH 4th, Roby KF, Roden RB. Yang R, et al. Cancer Res. 2006 Jul 1;66(13):6807-15. doi: 10.1158/0008-5472.CAN-05-3755. Cancer Res. 2006. PMID: 16818658

1. Yang R, Cai Z, Zhang Y, Yutzy WHt, Roby KF, Roden RB. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res. 2006;66:6807–15. - PubMed
1. Huang B, Pan PY, Li Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006;66:1123–31. - PubMed
1. Zea AH, Rodriguez PC, Atkins MB, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005;65:3044–8. - PubMed
1. Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 2005;65:9525–35. - PMC - PubMed
1. Mirza N, Fishman M, Fricke I, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006 September 15; in press. - PMC - PubMed